Prediagnostic circulating concentrations of plasma insulin‐like growth factor‐I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

Abstract

Insulin‐like growth factor (IGF)‐I has cancer promoting activities. However, the hypothesis that circulating IGF‐I concentration is related to risk of lymphoma overall or its subtypes has not been examined prospectively. IGF‐I concentration was measured in pre‐diagnostic plasma samples from a nested case–control study of 1,072 cases of lymphoid malignancies and 1,072 individually matched controls from the European Prospective Investigation into Cancer and Nutrition. Odds ratios (ORs) and confidence intervals (CIs) for lymphoma were calculated using conditional logistic regression. IGF‐I concentration was not associated with overall lymphoma risk (multivariable‐adjusted OR for highest versus lowest third = 0.77 [95% CI = 0.57–1.03], p trend = 0.06). There was no statistical evidence of heterogeneity in this association with IGF‐I by sex, age at blood collection, time between blood collection and diagnosis, age at diagnosis, or body mass index (p heterogeneity for all ≥ 0.05). There were no associations between IGF‐I concentration and risk for specific BCL subtypes, T‐cell lymphoma or Hodgkin lymphoma, although number of cases were small. In this European population, IGF‐I concentration was not associated with risk of overall lymphoma. This study provides the first prospective evidence on circulating IGF‐I concentrations and risk of lymphoma. Further prospective data are required to examine associations of IGF‐I concentrations with lymphoma subtypes.

Pre‐diagnostic circulating insulin‐like growth factor‐I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition

“…Moreover, a moderately large sample size allowed us to make reasonably precise estimates of the relationship between circulating IGF‐I concentrations and bladder cancer, while information on tumour subtypes enabled us to explore possible heterogeneity in bladder cancer risk by tumour aggressiveness. Finally, the distribution of circulating IGF‐I concentrations among controls in this study was similar to that observed in previous prospective studies …”

“…Finally, the distribution of circulating IGF-I concentrations among controls in this study was similar to that observed in previous prospective studies. 20,21 This study has some limitations. First, the analysis relied on a single measurement of circulating IGF-I in each participant.…”

Insulin‐like growth factor levels and chronic lymphocytic leukaemia: results from the MCC‐Spain and EpiLymph‐Spain studies

“…In particular, IGFs are powerful hormones that have been associated with growth, survival, apoptosis and migration of multiple myeloma cells (Vishwamitra et al , ) but data on CLL are both sparse and conflicting. To date, only one prospective study from the European Prospective Investigation into Cancer and Nutrition (EPIC) of 184 CLL cases and three very small case‐control studies (27, 77 and 43 CLL cases with 17, 27 and 21 controls, respectively) have been published on this topic (Schillaci et al , ; Molica et al , ; Ayer et al , ; Perez‐Cornago et al , ). No association between CLL and IGF‐I levels was observed in the EPIC study (Perez‐Cornago et al , ) and only one unpowered study (N = 47) has examined IGFBP‐3 in relation to CLL (Ayer et al , ) (summary in Table SI).…”

“…The stronger scientific evidence to date has been provided by the EPIC study, reporting no association between CLL and IGF‐I levels in samples taken up to 13 years before diagnosis (Perez‐Cornago et al , ). Hence, our findings might be due to reserve causality and IGF‐I levels might be a marker of disease progression (Molica et al , ).…”

Is ultrasound combined with computed tomography useful for distinguishing between primary thyroid lymphoma and Hashimoto’s thyroiditis?

“…Primary thyroid lymphoma (PTL) is a rare thyroid tumour, representing approximately 5% of all thyroid malignancies and accounting for less than 2% of extranodal malignant lymphomas [1][2][3]. Despite the rarity of PTL, it is important to recognise PTL promptly because of different management of all the other thyroid neoplasms [4].…”